Clinical TrialJun 24, 2026, 07:32 PM
Revolution Medicines to Present RAS(ON) Pipeline Data at ESMO GI Congress
AI Summary
Revolution Medicines announced it will present new data from its RAS(ON) pipeline at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress. The presentations include two oral presentations from Phase 1/2 trials evaluating zoldonrasib in combination regimens for metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). Additionally, two Phase 3 trials-in-progress posters for daraxonrasib in PDAC will be featured, highlighting its potential as a monotherapy or in combination for first-line treatment and as an adjuvant therapy.
Key Highlights
- Revolution Medicines to present four oral and poster presentations at ESMO GI Cancers Congress.
- Two oral presentations will feature Phase 1/2 data for zoldonrasib in metastatic RAS G12D PDAC.
- One oral presentation covers zoldonrasib plus chemotherapy in first-line mPDAC.
- Another oral presentation details zoldonrasib plus daraxonrasib in second-line+ mPDAC.
- Two posters will present Phase 3 trials-in-progress for daraxonrasib (RASolute 303 and RASolute 304).
- RASolute 303 evaluates daraxonrasib in first-line metastatic PDAC.
- RASolute 304 evaluates adjuvant daraxonrasib in resected PDAC.
Price Impact
More from RVMD